A Genotype-Phenotype Urothelial Cancer Registry

N/AActive Not RecruitingNCT00902590

Memorial Sloan Kettering Cancer Center3,519 enrolled

Overview

This study is being done to create a registry to help us learn more about urinary and other cancers. This will let us look at large groups of people who do and do not have this kind of cancer. The investigators will look at risk factors to learn more about how these impact cancer. The investigators will also look at genetic markers. These are genes that are found in a known place. They are often associated with a particular trait. If the gene changes in some way, it may predict cancer or response to treatment. The investigators will look for markers in your saliva. This registry will help us develop better methods of: Preventing these cancers. Diagnosing these cancers. Treating these cancers.

Study Type

OBSERVATIONAL

Enrollment

3,519

Conditions

Urothelial Cancer Renal Pelvis Cancer Ureter Cancer Bladder Cancer

Interventions

Urothelial Cancer Registry- Patients will complete a family history and urothelial cancer risk questionnaire, and will provide a buccal sample for germline DNA. If the cases have undergone germline sequencing as part of Protocol 12-245, they will not need to provide a buccal sample. If the cases have previously completed athe "the "Urothelial Baseline Questionnaire," in an MSKCC urology clinic they will not need to complete the urothelial cancer risk questionnaire.

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: Urothelial Cancer Cases * Must be ≥ 18 years of age AND * Must have a diagnosis of urothelial cancer AND * Must be an English-speaker Non-Cancer Control Group * Must be ≥ 18 years of age AND * Must not have cancer or a personal history of cancer, with the exception of skin cancer. AND * Must not be a blood relative of cases AND * Must not be a blood relative of another control AND * Must be an English-speaker Family Member Control Group: In select kindreds with a high prevalence of bladder cancer and/or very early onset bladder cancer, first- and second-degree family members of probands may be contacted by the MSKCC study team and invited to complete the questionnaire and submit a saliva sample. * Must be ≥ 18 years of age AND * Must be a blood relative of a case participant AND * Must be an English-speaker Exclusion Criteria: * Have any condition, which in the opinion of the primary MSKCC clinician or investigators precludes their ability to provide informed consent.

Locations (4)

Memorial Sloan Kettering Basking Ridge

Basking Ridge, New Jersey, United States

Memorial Sloan Kettering Commack

Commack, New York, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Memorial Sloan Kettering Nassau

Uniondale, New York, United States

Outcomes

Primary Outcomes

Determine whether single nucleotide polymorphisms in regions discovered from whole genome scans, such as 8q24 & chromosome 3, & candidate genes, include NAT2 & GSTM1, prev found to be assoc with bladder ca risk, are assoc with UC in this study population

Time frame: 2 years

Secondary Outcomes

To determine whether single nucleotide polymorphisms in the genes and regions listed above are associated with outcomes after UC diagnosis in the population

Time frame: 2 years